Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C

Most patients with chronic hepatitis C virus (HCV) infection have either already received antiviral treatment or are expected to receive treatment with direct-acting antivirals (DAAs) in the next 3-5 years in the United States. With sustained virologic response (SVR) rates well in excess of 90%, the vast majority of treated patients will achieve HCV eradication. SVR reduces hepatocellular carcinoma (HCC) risk substantially, irrespective of whether it is achieved by interferon (IFN) or DAA-based regimens[1].

Source: Journal of Hepatology - August 20, 2018 Category: Gastroenterology Authors: George N. Ioannou, Pamela K. Green, Lauren A. Beste, Elijah J. Mun, Kathleen F. Kerr, Kristin Berry Source Type: research